<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02751710</url>
  </required_header>
  <id_info>
    <org_study_id>OCOG-2016-PETABC</org_study_id>
    <nct_id>NCT02751710</nct_id>
  </id_info>
  <brief_title>Impact of 18F-FDG PET-CT Versus Conventional Staging in the Management of Patients Presenting With Clinical Stage III Breast Cancer</brief_title>
  <acronym>PET ABC</acronym>
  <official_title>Impact of 18F-FDG PET-CT Versus Conventional Staging in the Management of Patients Presenting With Clinical Stage III Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ontario Clinical Oncology Group (OCOG)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Care Ontario</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ontario Clinical Oncology Group (OCOG)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is being conducted to determine the impact of whole body FDG PET-CT vs.
      conventional staging in the management of patients presenting with clinical Stage III breast
      cancer. Eligible consenting patients with ductal or mixed histology breast cancer will be
      randomized 1:1 to whole body FDG PET-CT or conventional staging. Eligible consenting patients
      with lobular only histology will be entered into a separate single arm prospective study and
      will undergo whole body FDG PET-CT, CT with contrast of the chest/abdomen &amp; pelvis and a bone
      scan.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients upstaged to Stage IV disease</measure>
    <time_frame>Within 30 days from date of randomization</time_frame>
    <description>Proportion of patients upstaged to Stage IV disease as a result of the imaging study, between the groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who receive multimodal therapy of curative intent</measure>
    <time_frame>Within 12 months from date of randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of additional tests, such as imaging and biopsy, resulting from findings of study imaging</measure>
    <time_frame>Within 12 months from date of randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic ability of PET SUV of the primary lesion on the pathological response rate to neo-adjuvant chemotherapy</measure>
    <time_frame>Within 12 months from date of randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>From date of randomization to date of event, assessed up to 5 years</time_frame>
    <description>Objectively defined local or distance recurrence or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From date of randomization to date of event, assessed up to 5 years</time_frame>
    <description>Defined by all-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental economic analysis comparing the costs and outcomes of the treatment arms</measure>
    <time_frame>Within 5 years from date of randomization</time_frame>
    <description>Utility values will be collected using the EQ-5D Health Utility Questionnaire and converted to quality adjusted life years (QALYs) by considering Overall Survival. Direct medical resources (i.e. tests, complications, hospitalizations, clinic visits, emergency dept., etc.) will be obtained. Costs ($CAN2016) for each resource identified and utilized will be determined. Finally, an incremental cost-utility analysis will be calculated comparing the 2 randomized arms to generate an incremental cost per QALY outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">370</enrollment>
  <condition>Stage III Breast Cancer (T0N2, T1N2, T2N2, T3N1, 2 or T4)</condition>
  <condition>Stage IIb Breast Cancer (T3N0)</condition>
  <arm_group>
    <arm_group_label>Whole-body FDG PET-CT alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional breast cancer staging</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Conventional breast cancer staging consisting of a bone scan and CT imaging with contrast of the chest / abdomen &amp; pelvis</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Whole-body FDG PET-CT alone</intervention_name>
    <description>FDG PET-CT imaging</description>
    <arm_group_label>Whole-body FDG PET-CT alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women (or men) with histological evidence of breast cancer for whom potentially
             curative treatment is planned.

          -  Based on clinical information (physical exam, imaging):

               1. Stage III breast cancer (T0N2, T1N2, T2N2, T3N1, 2 or T4), or

               2. Stage IIb breast cancer (T3N0), Note: T2N1 is not eligible

          -  Considered for combined modality therapy (surgical resection, chemotherapy,
             radiotherapy) of curative intent.

        Exclusion Criteria:

          -  Age &lt; 18 years,

          -  ECOG performance status &gt; and = 3,

          -  Prior systemic therapy (e.g. neo-adjuvant chemotherapy or hormonal therapy) for
             current breast cancer,

          -  Previous staging investigations for current breast cancer,

          -  Breast cancer with primary histological subtypes other than ductal or lobular (Note:
             Patients with mixed disease will be eligible for randomization),

          -  Clinical suspicion of metastatic disease,

          -  Relative contraindications to PET (e.g. uncontrolled diabetes (i.e. inability to
             decrease serum glucose below 10.2 mmol/L), claustrophobia, inability to be still for
             30 minutes),

          -  Inability to lie supine for imaging with PET-CT,

          -  Inability to undergo CT because of known allergy to contrast,

          -  History of another invasive malignancy within the previous two years (exception of non
             melanoma skin cancer) or a synchronous primary cancer, including a synchronous
             contralateral breast cancer (Note: Patients found to have a contralateral breast
             cancer on study imaging following randomization will remain in the study),

          -  Known pregnancy or lactating female,

          -  Inability to complete the study or required follow-up.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ian Dayes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Juravinski Hospital and Cancer Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrea Eisen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ralph George, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Michael's Hospital, CIBC Breast Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ur Metser, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Princess Margaret Hospital, Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Levine, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ontario Clinical Oncology Group (OCOG)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marc L Filion, MSc</last_name>
    <phone>905-527-2299</phone>
    <phone_ext>42611</phone_ext>
    <email>filion@mcmaster.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juliet Woll, BHSc</last_name>
      <phone>905-387-9711</phone>
      <email>wollj@HHSC.CA</email>
    </contact>
    <investigator>
      <last_name>Bindi Dhesy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Becky Petrie</last_name>
      <phone>519-685-8618</phone>
      <email>rebecca.petrie@lhsc.on.ca</email>
    </contact>
    <investigator>
      <last_name>Phillip Blanchette, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Regional Cancer Centre</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luisa Ianni</last_name>
      <phone>613-798-5555</phone>
      <email>luianni@toh.ca</email>
    </contact>
    <investigator>
      <last_name>Angele Arnaout, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thunder Bay Regional Health Sciences Centre</name>
      <address>
        <city>Thunder Bay</city>
        <state>Ontario</state>
        <zip>P7B 6V4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Miedema, RN</last_name>
      <email>miedemal@tbh.net</email>
    </contact>
    <investigator>
      <last_name>Adrien Chan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Odette Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debra Burns</last_name>
      <email>debra.burns@sunnybrook.ca</email>
    </contact>
    <investigator>
      <last_name>Andrea Eisen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rehab Chahin</last_name>
      <phone>416-946-4501</phone>
      <email>Rehab.Chahin@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Tulin Cil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2016</study_first_submitted>
  <study_first_submitted_qc>April 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2016</study_first_posted>
  <last_update_submitted>December 21, 2017</last_update_submitted>
  <last_update_submitted_qc>December 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

